Edwards' heart valve shows long-term promise
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences says that it has become the first company to provide long-term data to show that its pericardial tissue heart valve continues to provide haemodynamic stability 17 years after implantation. The results add to previously reported 17-year data demonstrating the product's long-term durability, says the Irvine, California firm.